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Background: Cytokines and chemokines play important roles in asthma. However, 
little information exists on the effects of inhaled corticosteroids on cytokine and 
chemokine plasma levels in childhood asthma. We compared the pharmaceutical 
effects of two inhaled corticosteroids used in pediatric patients with mild-to-
moderate asthma, budesonide and fluticasone propionate.
Methods: Pediatric patients aged 5−18 years old were enrolled in this randomized, 
open-label, observer-blinded study and received 3 months of treatment with either 
inhaled budesonide (200 μg/puff) or fluticasone propionate (250 μg/puff), at two puffs 
per day. Peak expiratory flow (PEF), exhaled nitric oxide, Asthma Control Test (ACT), 
plasma levels of tumor necrosis factor-α, thymus and activation-regulated chemo-
kine, and interferon-inducible protein 10 were measured before treatment and 
monthly for 3 months after treatment.
Results: There were six patients in the budesonide group, and eight in the flutica-
sone group. After 3 months, both groups showed improved PEF. In the first month, 
PEF improved more in the budesonide group than in the fluticasone group, though 
the difference was not significant. After treatment, ACT scores in both groups were 
well controlled, except for one patient in the fluticasone group. The fluticasone 
group had a more significant reduction in exhaled nitric oxide than the budesonide 
group in the first month.
Conclusion: Improvements in lung function were more rapid in the budesonide 
group than the fluticasone group. However, patients in the fluticasone group had 
better anti-inflammatory responses than those in the budesonide group. We conclude 
that each inhaled corticosteroids have its own clinical and laboratory effects.
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1.  Introduction
Asthma is a chronic inflammatory disorder charac-
terized by airway hyperresponsiveness, airway in-
flammation, and reversible airway obstruction.1 
Tumor necrosis factor-α (TNF-α) functions as a pro-
inflammatory cytokine that leads to the recruitment 
of neutrophils and eosinophils in asthma.2 Elevated 
TNF-α levels have been detected in sputum, bron-
choalveolar lavage, and biopsy samples from asth-
matic patients.3 In addition to cytokines, chemokines 
also play an important role in asthma. Interferon-
inducible protein 10 (IP-10) also known as chemokine 
(C-X-C motif) ligand 10, is a Th1-related chemokine 
that plays an important and influential role in 
human allergic pulmonary reactions.4,5 Infiltration 
of the airways by Th2 lymphocytes is also a well-
recognized feature of bronchial asthma.6,7 Thymus 
and activation-regulated chemokine (TARC) is a Th2 
chemokine involved in the recruitment of CC chem-
okine receptor 4-bearing Th2 cells during allergen-
challenged inflammation.6,8
Asthma Control Test (ACT) scores have been 
clinically validated and are as sensitive as the 
pulmonary function test, which is the gold stand-
ard for monitoring asthma control. The ACT asks 
asthmatic patients to recall their asthma symp-
toms during the previous 4 weeks. Recent studies 
have shown that lower ACT scores are associated 
with poorer asthma outcomes, such as more 
emergency room visits and hospitalizations. Thus, 
ACT has become a useful tool in asthma 
management.9,10
As recommended by the Global Initiative Asthma 
(GINA) guidelines, a consensus protocol currently 
exists for anti-inflammatory treatment of child-
hood asthma.11 Inhaled glucocorticosteroids (ICS), 
the most effective medication available, can re-
duce asthma symptoms and exacerbations, and 
bronchial hyperresponsiveness; it can also also im-
prove lung function.11−13 The therapeutic effects 
of ICS are related to their ability to modulate im-
mune responses by altering the number of inflam-
matory cells and the expression of inflammatory 
mediators.14
Budesonide and fluticasone propionate are two 
inhaled glucocorticoid drugs that have been used in 
children with mild-to-moderate asthma for a long 
time. Plasma levels of TNF-α (pro-inflammatory), 
IP-10 (Th1) and TARC (Th2) increase during asthma 
exacerbations, and are thus used as inflammatory 
markers of asthma exacerbations in children. In 
the current study, we investigated the clinical re-
sponses that result from budesonide and fluticasone 
propionate treatment respectively, by comparing 
ACT results, exhaled nitric oxide (eNO) and peak 
expiratory flow (PEF). We also examined which 
agent produced a better anti-inflammatory effect 
in asthma patients by evaluating changes in plasma 
levels of TNF-α, TARC and IP-10.
2.  Materials and Methods
2.1.  Patients
The Institutional Review Board of Kaohsiung Medical 
University Hospital approved the study protocol 
(KMUH-IRB-960141). The study was conducted as an 
observer-blinded, randomized design, open-label 
cohort study. Pediatric patients aged 5−18 years 
old and who had suffered from asthma attacks be-
tween September 2007 and June 2008, were re-
cruited to the study. The children enrolled in this 
study were classified as having mild-to-moderate 
asthma, as defined by the GINA guidelines.11 
Participants who have had acute febrile respiratory 
tract infections or received previous cortico-steroid 
treatment were excluded; those hospitalized were 
also excluded from the study. A total of 20 children 
were randomly assigned to receive 3 months of treat-
ment with either fluticasone or budesonide in the 
outpatient clinic of our hospital. Informed consent 
was obtained from parents.
The clinical severity of asthma was defined as 
mildly persistent if symptoms were observed more 
than once per week; PEF was > 80% of the pre-
dicted or personal best, and PEF variability was 
between 20% and 30%. The severity was defined as 
moderately persistent if symptoms occurred daily, 
PEF was between 60% and 80% of predicted or per-
sonal best, and PEF variability was > 30%.
The childhood ACT is a seven-item assessment 
tool designed for children 4−11 years of age and is 
completed by the child and parent/caregiver.9 
Scores range from 0 to 27. For asthma patients 
aged 12 years and older, the ACT is a five-item 
patient-completed questionnaire that compares 
well with asthma specialists’ global assessment of 
asthma control; the measure is also responsive to 
changes in asthma control over time.10,15 Scores 
range from 0 to 25. In our study, asthma was defined 
as not controlled if the score was ≤ 19, well control-
led if the score was ≥ 20. Those who were febrile 
or received ICS were excluded. After parental 
informed consent was obtained, patients were 
followed for 3 consecutive months.
2.2.  Study design
Patients were divided into two randomized groups. 
One group was given 200 μg/puff budesonide 
(Obucort Swinghaler, Taiwan Otsuka Pharmaceutical 
Co. Ltd., Taipei, Taiwan). The other group was given 
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250 μg/puff fluticasone propionate (Flixotide 
Accuhaler, GlaxoSmithKline, Ware, UK). Both treat-
ments were administered twice per day. The dos-
ages of the two inhaled corticosteroids were 
equivalent to therapies for mild-to-moderate 
asthma, based on the GINA guidelines.11 PEF was 
measured using a peak flow meter (Astech Co., 
Port Washington, NY, USA), and eNO concentra-
tions were measured using the single-breath tech-
nique with a chemiluminescence analyzer (CLD 88 
Exhalyzer; Eco Medics AG, Dürnten, Switzerland). 
Plasma samples were stored at −70°C immediately 
after sampling. Plasma cytokine and chemokine 
levels were measured using a commercially avail-
able enzyme-linked immunosorbent assay systems 
(R&D Systems, Minneapolis, MN, USA). An inde-
pendent observer unaware of the grouping assign-
ment followed the patients and recorded the PEF 
and ACT results. ACT scores, PEF, eNO, and plasma 
levels of TNF-α, TARC, and IP-10 were measured 
both before (at the beginning of study) and after 
treatment (after 1, 2 and 3 months).
2.3.  Statistical analysis
SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) was 
used for all statistical analyses. Plasma levels of 
TNF-α, TARC, and IP-10 were analyzed using the 
Wilcoxon signed-rank test. Differences were con-
sidered significant when p < 0.05.
3.  Results
3.1.  Demographic data of subjects
Twenty patients were initially enrolled and 14 
completed the study. One patient was excluded 
due to active tuberculosis; five other patients 
were excluded due to lack of follow-up after the 
first month. The age distributions, body weights, 
and heights did not differ significantly between 
the two groups (Table 1). Patients who were eligi-
ble for the study were randomly assigned to re-
ceive either inhaled fluticasone propionate or 
budesonide for 3 months. Eight patients received 
fluticasone propionate (male:female, 6:2), and the 
other six patients received budesonide (male: 
female, 5:1). The age distributions did not differ 
significantly between the two groups (Table 1).
3.2.  Changes in eNO level after treatment
As shown in Figure 1A, eNO levels were significantly 
reduced after 1 month of fluticasone propionate 
treatment [47.95 ± 11.67 vs. 20.74 ± 3.87 parts per 
billion (ppb), p = 0.006], and after 2 months 
(47.95 ± 11.67 vs. 23.26 ± 12.68 ppb, p = 0.009). 
However, 1 month of treatment with budesonide 
significantly increased eNO levels (39.28 ± 6.20 vs. 
62.03 ± 12.08 ppb, p = 0.014), but after 3 months, 
eNO levels returned to a level similar to the pre-
treatment level (39.28 ± 6.20 vs. 38.38 ± 17.66 ppb, 
p = 0.447).
3.3.  Predicted PEF during the 
treatment course
A significant increase in predicted PEF occurred fol-
lowing 2 months of fluticasone propionate treatment 
(89.19 ± 9.58% vs. 97.65 ± 6.57 %, p = 0.047), and after 
3 months (89.19 ± 9.58% vs. 101.07 ± 8.02%, p = 0.01). 
Budesonide also significantly increased predicted 
PEF after the first (82.24 ± 6.28% vs. 102.86 ± 1.25%, 
p = 0.01), second (82.24 ± 6.28% vs. 105.26 ± 5.89%, 
p = 0.04), and third months (82.24 ± 6.28% vs. 
107.94 ± 5.64%, p = 0.02). The change in PEF after 
the first month was greater in the budesonide group, 
though the difference between the two groups was 
not significant.
3.4.  Changes in ACT scores after treatment
Patients were asked to complete the ACT test dur-
ing the treatment period. The ACT scores indicated 
good asthma control in both treatment groups, ex-
cept for one patient in the fluticasone propionate 
group (Table 2).
3.5.  Change in plasma TNF-a, TARC and 
IP-10 concentrations after treatment
Plasma TNF-α, IP-10 and TARC concentrations all 
increased in the first month in the budesonide 
group; however, the levels all declined to their 
baseline values in the third month (Figures 2A, 2B, 
and 2C). The fluticasone propionate group showed 
slight variations in plasma TNF-α, TARC and IP-10 
levels during the course of treatment.
TNF-α levels in the fluticasone propionate group 
remained low throughout the entire period, while 
TNF-α levels in the budesonide group increased in 
the first month and then gradually declined to the 
baseline value. The concentrations of IP-10 and 
Table 1 Demographic data
 Budesonide Fluticasone p
  propionate
Male:female 5:1 6:2 0.71
Age (yr) 10.2 ± 3.5 10.8 ± 4.0 0.77
Body height (cm) 135.0 ± 14.5 138.9 ± 23.2 0.71
Body weight (kg) 36.7 ± 9.6 47.1 ± 30.4 0.39
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TARC in the budesonide group increased in the first 
month and then declined to their baseline values in 
the third month. Budesonide significantly increased 
plasma TARC concentrations after the first 2 months 
of treatment (149.35 ± 38.48 vs. 180.52 ± 28.42 ppb, 
p = 0.01). Plasma TARC concentrations showed slight 
variations in the fluticasone propionate group. The 
IP-10 level in the fluticasone propionate group was 
lower than that of the budesonide group during the 
course of treatment. However, there were no sig-
nificant differences between the two groups in 
plasma TARC, IP-10 or TNF-α concentrations.
4.  Discussion
The use of ICS to reduce chronic inflammation is a 
cornerstone treatment for asthma.11 ICS can reduce 
asthma symptoms11−13 and inhibit the activities of 
inflammatory cells, including eosinophils, T lym-
phocytes, mast cells, macrophages, dendritic cells 
and neutrophils.16−18 Budesonide and fluticasone 
propionate have been effectively used to prevent 
the development of asthma in high-risk children.11,13 
In the present study, both groups showed improved 
PEF and well-controlled ACT scores, indicating that 
the two drugs could improve pulmonary function 
as well as clinical symptoms and signs.
PEF showed greater improvement in the budeso-
nide group than in the fluticasone group. The clinical 
efficacy of ICS depends on the topical activity of 
the drug that reaches the lungs. The amount of 
drug delivered to the lungs depends on the inhala-
tion technique, type of inhaler used, delivery of 
differently sized particles, and whether or not 
spacers are used.19 The Swinghaler is a high-delivery 
device with a low inspiratory flow that emits powder 
through a horizontal inhalation channel. The range 
of optimum inspiratory flow is widespread. Due to 
their different designs, the Swinghaler might be 
better than the Accuhaler in improving PEF.
Recent studies have shown that the bronchial 
epithelium in asthmatic patients expresses IP-10 
(a Th1-related-chemokine) and TARC (a Th2-related-
chemokine), which have been implicated in the re-
cruitment of Th1 and Th2 cells to inflammatory 
airways.4,20 TARC and IP-10 are useful inflammatory 
markers of asthma exacerbations in children.7,21 
TNF-α is expressed in various cells in asthmatic 
airways, particularly in mast cells, and it plays a 
Table 2 Results of Asthma Control Test scores at first, second and third months
 Category First month (n) Second month (n) Third month (n)
Fluticasone Well controlled 8 7 6
 Not controlled 0 1 0
Budesonide Well controlled 6 6 5
 Not controlled 0 0 0
Figure 1 Percentage changes in predicted peak expiratory flow (PEF) and exhaled nitric oxide [eNO; parts per billion 
(ppb)] before and after 1, 2 and 3 months of budesonide or fluticasone propionate treatment. (A) Fluticasone propion-
ate reduced eNO, in contrast to budesonide, which increased eNO after 1 month of treatment, and did not reduce 
eNO. (B) Both drugs improved percentages of predicted PEF after treatment. *p < 0.05.
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key role in amplifying asthmatic inflammation.22 
In the present study, plasma TNF-α, IP-10 and TARC 
increased after 1 month of treatment in the budes-
onide group, but declined to their baseline values 
after 3 months of treatment. In contrast, the fluti-
casone propionate group showed slight variations 
in plasma TNF-α, TARC and IP-10 levels during the 
course of treatment. With respect to eNO, ele-
vated eNO levels were observed in the budesonide 
group during the first and second months of treat-
ment, and the eNO levels almost declined to the 
pretreatment level in the third month; eNO level 
showed a decrease after treatment in the flutica-
sone group.
Of note was that in the current study, the eNO 
level was higher in the budesonide group than in 
the fluticasone group. Levels of eNO have been 
shown to correlate predominantly with eosinophilic 
airway inflammation, and can be reduced by 
ICS therapy.23 Moreover, eNO levels fell signifi-
cantly after treatment in the fluticasone propion-
ate group. Significantly elevated eNO levels were 
observed in the budesonide group during the first 
month of treatment, although it fell almost to the 
pretreatment level in the third month. Fluticasone 
was shown to maintain TNF-α, IP-10 and TARC at 
constant levels, whereas budesonide led to ele-
vated levels of TNF-α and TARC during treatment. 
Taken together, these observations suggest that flu-
ticasone propionate had a greater anti-inflammatory 
effect than budesonide in our study. Factors such 
as nitrate-containing foods or allergic rhinitis can 
influence the concentration of eNO;24 these fac-
tors could potentially account for the observation 
that eNO levels were elevated in the budesonide 
group, despite clinical improvements.
Budesonide and fluticasone propionate are both 
ICS, but they demonstrated divergent effects in 
this study. The two kinds of ICS have close chemical 
and structural similarities. However, they use differ-
ent pharmacokinetic and delivery device designs, 
which could lead to differences in their clinical ef-
fects. Potency, a measure of the microgram dose 
of a drug required to produce a standard response, 
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Figure 2  Changes in (A) plasma thymus and activation-
regulated chemokine (TARC), (B) interferon-inducible 
protein 10 (IP-10) and (C) tumor necrosis factor (TNF)-α 
levels before and after fluticasone propionate and 
budesonide treatment. Budesonide increased plasma 
TARC, IP-10 and TNF-α levels after treatment for 1 
month, but they fell to slightly below baseline, pretreat-
ment levels after treatment for 3 months. Fluticasone 
propionate treatment led to variations in the levels of 
these proteins during the course of treatment. *p < 0.05.
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is greater for fluticasone propionate than for 
budesonide.25 In comparison to budesonide, flutica-
sone propionate also exhibits considerably greater 
glucocorticoid receptor-binding affinity,25 and has 
been demonstrated to have a longer lung retention 
time.26 Thus, these factors could account for the 
superior anti-inflammatory effect of fluticasone 
propionate compared with budesonide.
There were several limitations to the current 
study. Due to the frequent blood-sampling require-
ments, the total number of patients that com-
pleted this study was small because some patients 
refused to continue with the protocol. Also, PEF 
tests were difficult to perform in patients younger 
than 6 years old. Drug compliance also tends to be 
particularly variable in pediatric patients. Further 
limitations also includes confounding factors such 
as environmental effects or allergen avoidance, 
which could not be eliminated.
In conclusion, patients in the budesonide group 
had greater improvements in lung function, and 
clinical symptoms and signs than those in the fluti-
casone propionate group. Nevertheless, the fluti-
casone propionate group experienced a better 
anti-inflammatory response than the budesonide 
group. We conclude that the two different ICSs 
have divergent clinical and laboratory effects.
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